22,925 Shares in CymaBay Therapeutics Inc (NASDAQ:CBAY) Purchased by National Asset Management Inc.

Share on StockTwits

National Asset Management Inc. purchased a new position in shares of CymaBay Therapeutics Inc (NASDAQ:CBAY) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 22,925 shares of the biopharmaceutical company’s stock, valued at approximately $165,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Meeder Asset Management Inc. raised its holdings in CymaBay Therapeutics by 307.3% in the first quarter. Meeder Asset Management Inc. now owns 2,839 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 2,142 shares in the last quarter. Swiss National Bank lifted its holdings in CymaBay Therapeutics by 2.1% in the second quarter. Swiss National Bank now owns 112,900 shares of the biopharmaceutical company’s stock valued at $808,000 after acquiring an additional 2,300 shares during the period. Bank of America Corp DE raised its stake in shares of CymaBay Therapeutics by 1.5% in the fourth quarter. Bank of America Corp DE now owns 164,192 shares of the biopharmaceutical company’s stock worth $1,291,000 after buying an additional 2,478 shares during the period. Marshall Wace LLP raised its stake in CymaBay Therapeutics by 17.0% during the 1st quarter. Marshall Wace LLP now owns 63,589 shares of the biopharmaceutical company’s stock valued at $844,000 after purchasing an additional 9,231 shares during the period. Finally, BNP Paribas Arbitrage SA bought a new stake in CymaBay Therapeutics during the 1st quarter valued at approximately $165,000. 96.07% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CBAY traded up $0.03 during midday trading on Wednesday, reaching $5.53. 14,400 shares of the stock were exchanged, compared to its average volume of 568,565. The business’s 50-day moving average price is $6.09 and its 200 day moving average price is $9.96. The company has a debt-to-equity ratio of 0.01, a current ratio of 16.20 and a quick ratio of 16.20. CymaBay Therapeutics Inc has a twelve month low of $4.82 and a twelve month high of $14.00. The company has a market capitalization of $379.92 million, a price-to-earnings ratio of -4.39 and a beta of 1.20.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. As a group, equities research analysts expect that CymaBay Therapeutics Inc will post -1.47 earnings per share for the current fiscal year.

A number of equities analysts have recently commented on CBAY shares. ValuEngine upgraded CymaBay Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Stifel Nicolaus began coverage on CymaBay Therapeutics in a report on Monday, June 24th. They set a “buy” rating and a $14.00 price objective for the company. Oppenheimer set a $12.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 11th. B. Riley set a $7.00 price objective on CymaBay Therapeutics and gave the company a “hold” rating in a report on Monday, June 17th. Finally, BidaskClub cut CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $14.09.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

Recommended Story: What is a stock split?

Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Reata Pharmaceuticals Inc to Post FY2019 Earnings of  Per Share, Cantor Fitzgerald Forecasts
Reata Pharmaceuticals Inc to Post FY2019 Earnings of Per Share, Cantor Fitzgerald Forecasts
CGI Inc  Holdings Decreased by Financial Gravity Wealth Inc.
CGI Inc Holdings Decreased by Financial Gravity Wealth Inc.
Brokers Offer Predictions for Astronics Co.’s Q3 2019 Earnings
Brokers Offer Predictions for Astronics Co.’s Q3 2019 Earnings
FY2019 EPS Estimates for Timkensteel Corp Cut by G.Research
FY2019 EPS Estimates for Timkensteel Corp Cut by G.Research
Capital Investment Services of America Inc. Sells 3,425 Shares of Microsoft Co.
Capital Investment Services of America Inc. Sells 3,425 Shares of Microsoft Co.
Pacer Advisors Inc. Grows Stock Holdings in Hologic, Inc.
Pacer Advisors Inc. Grows Stock Holdings in Hologic, Inc.


© 2006-2019 Ticker Report